The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients

References

• Campo G, Pavasini R, Malagù M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29:147–157.
   PubMed Web of Science ®Google Scholar
• Blanco I, Piccari L, Barberà JA. Pulmonary vasculature in COPD: the silent component. Respirology. 2016;21:984–994.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–1185.
   PubMed Web of Science ®Google Scholar
• Florey L. The endothelial cell. Br Med J. 1966;2:487–490.
   PubMed Web of Science ®Google Scholar
• Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332–1339.
   PubMed Web of Science ®Google Scholar
• Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertens (Dallas, Tex 1979). 1994;23:1121–1131.
   PubMed Web of Science ®Google Scholar
• Reis SE, Holubkov R, Lee JS, et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women’s Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol. 1999;33:1469–1475.
   PubMed Web of Science ®Google Scholar
• Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. Circulation. 2000;101:1261–1266.
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639–646.
   PubMed Web of Science ®Google Scholar
• Barberà JA, Peinado VI, Santos S, et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med. 2001;164:709–713.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114–1118.
   PubMed Web of Science ®Google Scholar
• Willis AL, Smith DL, Vigo C, et al. Effects of prostacyclin and orally active stable mimetic agent RS-93427-007 on basic mechanisms of atherogenesis. Lancet (London, England). 1986;2:682–683.
   PubMed Web of Science ®Google Scholar
• Gleim S, Kasza Z, Martin K, et al. Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep. 2009;11:227–235.
   PubMed Web of Science ®Google Scholar
• Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets. 2011;12:501–513.
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Lee JD, Sotto-Santiago S, et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med. 2007;175:676–685.
   PubMed Web of Science ®Google Scholar
• Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046–1051.
   PubMed Web of Science ®Google Scholar
• Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990;81:1586–1593.
   PubMed Web of Science ®Google Scholar
• Cohen RA, Zitnay KM, Haudenschild CC, et al. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ Res. 1988;63:903–910.
   PubMed Web of Science ®Google Scholar
• Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618–623.
   PubMed Web of Science ®Google Scholar
• Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31:352–358.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. Jama. 1994;272:1497–1505.
   PubMed Web of Science ®Google Scholar
• Sackett DL, Gibson RW, Bross ID, et al. Relation between aortic atherosclerosis and the use of cigarettes and alcohol. An autopsy study. N Engl J Med. 1968;279:1413–1420.
   PubMed Web of Science ®Google Scholar
• Auerbach O, Hammond EC, Garfinkel L. Smoking in relation to atherosclerosis of the coronary arteries. N Engl J Med. 1965;273:775–779.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091–1097.
   PubMed Web of Science ®Google Scholar
• Vivodtzev I, Tamisier R, Baguet J-P, et al. Arterial stiffness in COPD. Chest. 2014;145:861–875.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. Copd. 2005;2:35–41.
   PubMedGoogle Scholar
• Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.
   PubMed Web of Science ®Google Scholar
• Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J. 2011;32:2365–2375.
   PubMed Web of Science ®Google Scholar
• Antonelli Incalzi R, Fuso L, de Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794–2800.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–969.
   PubMed Web of Science ®Google Scholar
• Pastor MD, Nogal A, Molina-Pinelo S, et al. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. Int J Mol Sci. 2013;14:3440–3455.
   PubMed Web of Science ®Google Scholar
• Pavasini R, D’Ascenzo F, Campo G, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol. 2015;191:187–193.
   PubMed Web of Science ®Google Scholar
• Suwa T, Hogg JC, Quinlan KB, et al. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol. 2002;39:935–942.
   PubMed Web of Science ®Google Scholar
• Kido T, Tamagawa E, Bai N, et al. Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am J Respir Cell Mol Biol. 2011;44:197–204.
   PubMed Web of Science ®Google Scholar
• Barberà JA. Chronic obstructive pulmonary disease: a disease of the endothelium? Am J Respir Crit Care Med. 2013;188:5–7.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719–725.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672–688.
   PubMed Web of Science ®Google Scholar
• Domej W, Oettl K, Renner W. Oxidative stress and free radicals in COPD–implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis. 2014;9:1207–1224.
   PubMed Web of Science ®Google Scholar
• Russell REK, S V C, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602–609.
   PubMed Web of Science ®Google Scholar
• Boots AW, Haenen GRMM, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:14s–27s.
   PubMedGoogle Scholar
• Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta. 2012;1822:714–728.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:813–816.
   PubMed Web of Science ®Google Scholar
• Boschetto P, Beghé B, Fabbri LM, et al. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012;17:422–431.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71–86.
   PubMed Web of Science ®Google Scholar
• Vlahos R, Bozinovski S. Recent advances in pre-clinical mouse models of COPD. Clin Sci (Lond). 2014;126:253–265.
   PubMed Web of Science ®Google Scholar
• Vlahos R, Bozinovski S, Hamilton JA, et al. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther. 2006;112:106–115.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543–559.
   PubMed Web of Science ®Google Scholar
• Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 2000;15:274–280.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:349–355.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84:210–215.
   PubMed Web of Science ®Google Scholar
• Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001;56:721–726.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120.
   PubMed Web of Science ®Google Scholar
• Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001;56:36–41.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–580.
   PubMed Web of Science ®Google Scholar
• Austin V, Crack PJ, Bozinovski S, et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links?. Clin Sci (Lond). 2016;130:1039–1050.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309:2353–2361.
   PubMed Web of Science ®Google Scholar
• Foster GE, Hanly PJ, Ahmed SB, et al. Intermittent hypoxia increases arterial blood pressure in humans through a renin-angiotensin system-dependent mechanism. Hypertension. 2010;56(3):369–377.
   Web of Science ®Google Scholar
• Santos S, Peinado VI, Ramírez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632–638.
   PubMed Web of Science ®Google Scholar
• Peinado VI, Barberá JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1605–1611.
   PubMed Web of Science ®Google Scholar
• Wagner EM, Mitzner WA. Effect of hypoxia on bronchial circulation. J Appl Physiol. 1988;65:1627–1633.
   PubMed Web of Science ®Google Scholar
• Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259–1265.
   PubMed Web of Science ®Google Scholar
• Miner SES, Al-Hesayen A, Nield LE, et al. Acetylcholine acutely modifies nitric oxide synthase function in the human coronary circulation. Exp Physiol. 2010;95:1167–1176.
   PubMed Web of Science ®Google Scholar
• Stein CM, Brown N, Vaughan DE, et al. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol. 1998;32:117–122.
   PubMed Web of Science ®Google Scholar
• Stabenfeldt SE, Gossett JJ, Barker TH. Building better fibrin knob mimics: an investigation of synthetic fibrin knob peptide structures in solution and their dynamic binding with fibrinogen/fibrin holes. Blood. 2010;116:1352–1359.
   PubMed Web of Science ®Google Scholar
• André P. P-selectin in haemostasis. Br J Haematol. 2004;126:298–306.
   PubMed Web of Science ®Google Scholar
• Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107:85–97.
   PubMed Web of Science ®Google Scholar
• Gimbrone MA, Bevilacqua MP, Cybulsky MI. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann N Y Acad Sci. 1990;598:77–85.
   PubMed Web of Science ®Google Scholar
• Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–197.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–519.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219–4225.
   PubMed Web of Science ®Google Scholar
• Peinado VI, Ramírez J, Roca J, et al. Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2006;34:257–263.
   PubMed Web of Science ®Google Scholar
• Marwick JA, Stevenson CS, Giddings J, et al. Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Am J Physiol Lung Cell Mol Physiol. 2006;290:L897–908.
   PubMed Web of Science ®Google Scholar
• Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003;23:1185–1189.
   PubMed Web of Science ®Google Scholar
• Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.
   PubMed Web of Science ®Google Scholar
• Heiss C, Keymel S, Niesler U, et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441–1448.
   PubMed Web of Science ®Google Scholar
• Murasawa S, Kawamoto A, Horii M, et al. Niche-dependent translineage commitment of endothelial progenitor cells, not cell fusion in general, into myocardial lineage cells. Arterioscler Thromb Vasc Biol. 2005;25:1388–1394.
   PubMed Web of Science ®Google Scholar
• Asosingh K, Swaidani S, Aronica M, et al. Th1- and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol. 2007;178:6482–6494.
   PubMed Web of Science ®Google Scholar
• Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function. J Am Coll Cardiol. 2008;51:1760–1771.
   PubMed Web of Science ®Google Scholar
• Caramori G, Rigolin GM, Mazzoni F, et al. Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD. Thorax. 2010;65:554–555.
   PubMed Web of Science ®Google Scholar
• Paschalaki KE, Starke RD, Hu Y, et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells. 2013;31:2813–2826.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56:515–548.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Tuder RM, Cool CD, et al. Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. Chest. 2000;117:260S.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737–744.
   PubMed Web of Science ®Google Scholar
• Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17:946–953.
   PubMed Web of Science ®Google Scholar
• Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol. 2003;28:555–562.
   PubMed Web of Science ®Google Scholar
• Plataki M, Tzortzaki E, Rytila P, et al. Apoptotic mechanisms in the pathogenesis of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:161–171.
   PubMedGoogle Scholar
• Morissette MC, Parent J, Milot J. Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know. Int J Chron Obstruct Pulmon Dis. 2009;4:19–31.
   PubMedGoogle Scholar
• Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: the vascular story. Pulm Circ. 2011;1:320–326.
   PubMedGoogle Scholar
• Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood. 2002;99:2455–2458.
   PubMed Web of Science ®Google Scholar
• Chironi GN, Boulanger CM, Simon A, et al. Endothelial microparticles in diseases. Cell Tissue Res. 2009;335:143–151.
   PubMed Web of Science ®Google Scholar
• Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175–180.
   PubMed Web of Science ®Google Scholar
• Horstman LL, Jy W, Jimenez JJ, et al. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 2004;9:1118–1135.
   PubMed Web of Science ®Google Scholar
• Gordon C, Gudi K, Krause A, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med. 2011;184:224–232.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kobayashi S, Fujino N, et al. Increased circulating endothelial microparticles in COPD patients: a potential biomarker for COPD exacerbation susceptibility. Thorax. 2012;67:1067–1074.
   PubMed Web of Science ®Google Scholar
• Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829–37,837a–837d.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:S49–73.
   PubMed Web of Science ®Google Scholar
• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2010;56:e50–103.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127:143–152.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120:502–509.
   PubMed Web of Science ®Google Scholar
• Huang AL, Silver AE, Shvenke E, et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol. 2007;27:2113–2119.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation. 2011;123:163–169.
   PubMed Web of Science ®Google Scholar
• Lind L, Berglund L, Larsson A, et al. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation. 2011;123:1545–1551.
   PubMed Web of Science ®Google Scholar
• Pijls NHJ, De Bruyne B, Smith L, et al. Coronary thermodilution to assess flow reserve: validation in humans. Circulation. 2002;105:2482–2486.
   PubMed Web of Science ®Google Scholar
• Aarnoudse W, Van’t Veer M, Pijls NHJ, et al. Direct volumetric blood flow measurement in coronary arteries by thermodilution. J Am Coll Cardiol. 2007;50:2294–2304.
   PubMed Web of Science ®Google Scholar
• Mullen MJ, Kharbanda RK, Cross J, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88:145–151.
   PubMed Web of Science ®Google Scholar
• Arrebola-Moreno AL, Laclaustra M, Kaski JC. Noninvasive assessment of endothelial function in clinical practice. Rev Española Cardiol (English Ed). 2012;65:80–90.
   PubMed Web of Science ®Google Scholar
• Mattace-Raso FUS, Van Der Cammen TJM, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–663.
   PubMed Web of Science ®Google Scholar
• Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664–670.
   PubMed Web of Science ®Google Scholar
• Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. 2011;18:775–789.
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126:753–767.
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168–174.
   PubMed Web of Science ®Google Scholar
• Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Prev Cardiol. 2011;18:775–789.
   Web of Science ®Google Scholar
• Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–3777.
   PubMed Web of Science ®Google Scholar
• Lemichez E, Lecuit M, Nassif X, et al. Breaking the wall: targeting of the endothelium by pathogenic bacteria. Nat Rev Microbiol. 2010;8:93–104.
   PubMed Web of Science ®Google Scholar
• Hunter KA, Garlick PJ, Broom I, et al. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci (Lond). 2001;100:459–465.
   PubMed Web of Science ®Google Scholar
• Hung J, Lam JY, Lacoste L, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92:2432–2436.
   PubMed Web of Science ®Google Scholar
• Harding SA, Sarma J, Josephs DH, et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004;109:1926–1929.
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769–774.
   PubMed Web of Science ®Google Scholar
• Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923–929.
   PubMed Web of Science ®Google Scholar
• Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res. 2006;118:487–493.
   PubMed Web of Science ®Google Scholar
• Hutton RA, Mikhailidis DP, Bernstein RM, et al. Assessment of platelet function in patients with Raynaud’s syndrome. J Clin Pathol. 1984;37:182–187.
   PubMed Web of Science ®Google Scholar
• Onder I, Topcu S, Dökmetas HS, et al. Platelet aggregation size and volume in chronic obstructive pulmonary disease. Mater Med Pol. 1997;29:11–13.
   PubMedGoogle Scholar
• Ogawa S, Shreeniwas R, Brett J, et al. The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br J Haematol. 1990;75:517–524.
   PubMed Web of Science ®Google Scholar
• McDonald TP, Cottrell M, Clift R. Effects of short-term hypoxia on platelet counts of mice. Blood. 1978;51:165–175.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax. 1991;46:504–507.
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Pollina A, et al. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013;132:151–157.
   PubMed Web of Science ®Google Scholar
• Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96:776–781.
   PubMed Web of Science ®Google Scholar
• Milovanovic M, Nilsson E, Järemo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta. 2004;343:237–240.
   PubMed Web of Science ®Google Scholar
• Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010;21:122–125.
   PubMed Web of Science ®Google Scholar
• Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75:291–294.
   PubMed Web of Science ®Google Scholar
• Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404.
   PubMed Web of Science ®Google Scholar
• Bath P, Algert C, Chapman N, et al. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;35:622–626.
   PubMed Web of Science ®Google Scholar
• Thompson CB, Jakubowski JA, Quinn PG, et al. Platelet size and age determine platelet function independently. Blood. 1984;63:1372–1375.
   PubMed Web of Science ®Google Scholar
• Kodiatte TA, Manikyam UK, Rao SB, et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012;4:5–9.
   PubMedGoogle Scholar
• Hekimsoy Z, Payzin B, Ornek T, et al. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications. 2004;18:173–176.
   PubMed Web of Science ®Google Scholar
• Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–2188.
   PubMed Web of Science ®Google Scholar
• Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol. 2009;31:277–297.
   PubMed Web of Science ®Google Scholar
• Thompson CB, Eaton KA, Princiotta SM, et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol. 1982;50:509–519.
   PubMed Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Jagroop IA, et al. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9:177–190.
   PubMed Web of Science ®Google Scholar
• Jagroop IA, Clatworthy I, Lewin J, et al. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets. 2000;11:28–32.
   PubMed Web of Science ®Google Scholar
• Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13:301–306.
   PubMed Web of Science ®Google Scholar
• Schoene NW. Design criteria: tests used to assess platelet function. Am J Clin Nutr. 1997;65:1665S–1668S.
   PubMed Web of Science ®Google Scholar
• Martin JF, Trowbridge EA, Salmon G, et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32:443–460.
   PubMed Web of Science ®Google Scholar
• Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24:69–72.
   PubMed Web of Science ®Google Scholar
• Cui H, Liu L, Wei Z, et al. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr. 2012;54:e109–12.
   PubMed Web of Science ®Google Scholar
• Steiropoulos P, Papanas N, Nena E, et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Angiology. 2013;64:535–539.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Cotter FE, Empey DW. Platelet size in patients with chronic airflow obstruction with and without hypoxaemia. Thorax. 1988;43:61–64.
   PubMed Web of Science ®Google Scholar
• Agapakis DI, Massa EV, Hantzis I, et al. The role of mean platelet volume in chronic obstructive pulmonary disease exacerbation. Respir Care. 2016;61:44–49.
   PubMed Web of Science ®Google Scholar
• Malerba M, Olivini A, Radaeli A, et al. Platelet activation and cardiovascular comorbidities in patients with chronic obstructive pulmonary disease. Curr Med Res Opin. 2016;32:885–891.
   PubMed Web of Science ®Google Scholar
• Ulasli SS, Ozyurek BA, Yilmaz EB, et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med WewnęTrznej. 2012;122:284–290.
   PubMed Web of Science ®Google Scholar
• Wang R, Li J-Y, Cao Z, et al. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18:1244–1248.
   PubMed Web of Science ®Google Scholar
• Biljak VR, Pancirov D, Cepelak I, et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22:466–470.
   PubMed Web of Science ®Google Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69:609–615.
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol. 2009;131:834–842.
   PubMed Web of Science ®Google Scholar
• Lardi E, Ott C, Schulzki T, et al. Acute effects of short-term exposure to second-hand smoke on induced platelet aggregation. Clin Hemorheol Microcirc. 2010;45:359–364.
   PubMed Web of Science ®Google Scholar
• Kim V, Goel N, Gangar J, et al. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis (Miami, Fla). 2014;1:239–249.
   PubMedGoogle Scholar
• Lankeit M, Held M. Incidence of venous thromboembolism in COPD: linking inflammation and thrombosis? Eur Respir J [Internet]. 2016;47:369–373. cited 2016 Dec 14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26828045
   PubMed Web of Science ®Google Scholar
• Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case–control study. J Thromb Haemost. 2006;4:1914–1918.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA J Am Med Assoc [Internet]. 1997;277:642. cited 2016 Dec 14. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.1997.03540320044033
   PubMed Web of Science ®Google Scholar
• Malerba M, Clini E, Malagola M, et al. Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. Expert Rev Hematol. 2013;6:475–483.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Sheng X, Murphy MJ, MacDonald TM, et al. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all-cause mortality in chronic obstructive pulmonary disease: a population-based cohort study. Clin Ther. 2012;34:374–384.
   PubMed Web of Science ®Google Scholar
• Lawes CMM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J. 2012;21:35–40.
   PubMedGoogle Scholar
• Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29:279–283.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210.
   PubMed Web of Science ®Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NPA, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880–887.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301–305.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145:695–703.
   PubMed Web of Science ®Google Scholar
• Lehman A, Mattman A, Sin D, et al. Emphysema in an adult with galactosialidosis linked to a defect in primary elastic fiber assembly. Mol Genet Metab. 2012;106:99–103.
   PubMed Web of Science ®Google Scholar
• Podowski M, Calvi C, Metzger S, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122:229–240.
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Pollina A, et al. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014;69:80–81.
   PubMed Web of Science ®Google Scholar
• Andell P, James SK, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015;4:e002490.
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, D’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD J Chronic Obstr Pulm Dis. 2016;13:509–514.
   PubMed Web of Science ®Google Scholar